English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Ischemic heart disease is the leading cause of death worldwide. Chronic or acute occlusion of a coronary artery results in a shortage of oxygen and nutrient supply to some areas of the heart, leading to dramatic myocardial remodeling that includes disturbances of electrical conduction, cardiomyocyte death, inflammation and fibrosis. In most cases, the therapeutic strategy involves primary percutaneous coronary intervention (PCI) in order to open up the obstructed coronary artery and restore blood flow. The clinical decision to proceed with PCI is based on the patient’s electrocardiographic profile and levels of circulating markers at the time of diagnosis that denote the presence of cardiac lesion. It is therefore of the utmost importance to identify new blood markers that reveal mechanisms of cardiomyocyte injury. Cardiac imaging modalities such as positron emission tomography are also important for assessing the myocardial perfusion profile, which reflects the extent of the damage, helping to establish an accurate prognosis as well as the most appropriate therapeutic approach to improve patient outcomes. Although reperfusion by PCI remains the gold standard for treating ischemia-related injury, it is often

A novel cardioprotective strategy targeting mitochondrial reactive oxygen species production independent of antioxidant activity